---
layout: default
title: Antimony Trisulfide Benzoic Acid Ledum Palustre Tw
parent: 僅模型預測 (L5)
nav_order: 357
evidence_level: L5
indication_count: 0
---

# Antimony Trisulfide Benzoic Acid Ledum Palustre Tw
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Homeopathic Combination: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This Evidence Pack contains a seven-component combination product (including Antimony Trisulfide, Benzoic Acid, Ledum Palustre, Quercus Robur, Rhododendron Aureum, Silicon Dioxide, and Strychnos Nux-Vomica) that appears to be a homeopathic formulation.
The TxGNN model returned **no predicted indications** for this submission, and no original indications, regulatory approvals, or safety records were identified.
Without a valid DrugBank ID or recognized active pharmaceutical ingredient mapping, this candidate cannot be assessed under the standard repurposing framework.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no predictions, no studies identified) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN model relies on mapping submitted drug names to DrugBank IDs, which are then located within a biomedical knowledge graph to generate disease predictions. This submission failed to complete that pipeline for the following reasons:

**1. No DrugBank ID resolved.** The submitted string is a semicolon-delimited list of seven ingredients — none of which resolved to a single DrugBank entry. TxGNN requires a unique, mappable compound node to traverse the knowledge graph.

**2. Homeopathic and botanical components.** Several ingredients (Ledum palustre twig, Quercus robur flower, Rhododendron aureum leaf, Strychnos nux-vomica seed) are classical homeopathic remedies used in highly diluted form. These substances are not represented as standard pharmacological nodes in the TxGNN knowledge graph, which is built on conventional drug–disease relationships.

**3. Inactive and excipient components.** Silicon dioxide is a pharmaceutical excipient with no therapeutic target. Benzoic acid at typical formulation concentrations is an antimicrobial preservative, not a primary active ingredient. Including these alongside botanical materials further prevents clean ingredient-level mapping.

**4. No original indication to anchor repurposing logic.** The standard repurposing evaluation asks: "given this drug's proven efficacy in Indication A, can the same mechanism explain efficacy in Indication B?" Without a validated original indication, this reasoning chain cannot begin.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This submission cannot enter the TxGNN repurposing pipeline as currently structured. The product appears to be a multi-ingredient homeopathic preparation with no DrugBank representation, no regulatory approval in any surveyed jurisdiction, and no clinical evidence base. The TxGNN model returned zero predicted indications, making downstream evaluation impossible.

**To proceed, the following is needed:**

- **Clarify the intended active ingredient.** If one specific component (e.g., Nux vomica alkaloids, antimony compounds) is the therapeutic focus, resubmit with that single ingredient's INN and obtain its DrugBank ID.
- **Confirm product category.** If this is a registered homeopathic product in any country, provide the relevant national registry number so regulatory context can be established.
- **Obtain MOA documentation.** If a plausible pharmacological mechanism exists for any component, provide the source (DrugBank, peer-reviewed literature) so TxGNN graph traversal can be attempted manually.
- **Verify market status.** Query the originating country's drug registry (e.g., Taiwan TFDA, EU HMPC, US HHS/FDA homeopathic listings) to confirm whether any license has ever been issued for this combination.
- **Safety assessment prerequisite.** If this product contains Strychnos nux-vomica at a non-homeopathic (pharmacologically active) dose, strychnine toxicity data must be reviewed before any repurposing discussion proceeds. This is a safety blocker regardless of indication.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

